2021使用者論文發表 (由新到舊)
Genome-Wide Epigenetic Landscape of Lung Adenocarcinoma Links HOXB9 DNA Methylation to Intrinsic EGFR-TKI Resistance and Heterogeneous Responses.
https://ascopubs.org/doi/full/10.1200/PO.20.00151
IKKε isoform switching governs the immune response against EV71 infection.
https://www.nature.com/articles/s42003-021-02187-x
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 study.
https://pubmed.ncbi.nlm.nih.gov/34093743/
The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M.
https://pubmed.ncbi.nlm.nih.gov/34103652/
Primary Tumor Resection Is Associated with a Better Outcome among Advanced EGFR-Mutant Lung Adenocarcinoma Patients Receiving EGFR-TKI Treatment.
https://pubmed.ncbi.nlm.nih.gov/32894845/
Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia with kinase fusions in Taiwan.
https://www.nature.com/articles/s41598-021-85213-6
Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients.
https://pubmed.ncbi.nlm.nih.gov/33790577/
PCDH10 exerts tumor-suppressor functions through modulation of EGFR/AKT axis in colorectal cancer.
https://pubmed.ncbi.nlm.nih.gov/33271263/
近期服務亮點與規劃
協助國內外大型基因體學研究整合:
1. 癌症登月二期計畫(中研院)
2. 健康大數據永續平台計畫(中山醫科大學)
3. 創新轉譯研究主軸推動計畫(台灣大學)
支持台灣精準醫學檢驗升級:
1. 南港生技園區計畫(甲狀腺球蛋白與癌症起始基因突變蛋白檢測平台)
2. LifeOS產學計畫與中科計畫(ddPCR 癌症組織與液態活檢基因突變檢測)
3. 中山附醫產學合作計畫(NGS LDTS實驗室建立)
國際合作提升基因蛋白平台:
1. 工合計劃(NAPPA蛋白晶片平台)
2. 液態活檢DNA與RNA突變技術建立
臨床試驗案:
Retevmo 臨床試驗案【Lilly_J2G-MC-JZJC 】、Gavreto 臨床試驗案【Blueprint_BLU-667-2303】
臨床服務案:
國內醫院--EGFR基因檢測及NGS癌症基因檢測、ALK IHC、BRAF及HER2基因檢測